BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors

BioCryst is filling its coffers again — this time in $350 million cash with the help of both old and new investors.

The Durham, NC biotech reported this morning that it inked yet another deal alongside a familiar name — Royalty Pharma for $200 million. Royalty was the same company that paid $125 million to BioCryst $BCRX last year in exchange for profits from the then-recently approved oral HAE drug Orladeyo.